Treatment of Autosomal Dominant Familial Diabetes due to HNF1A Mutation (MODY3) with Postprandial Hyperglycemia

This protocol covers monogenic diabetes presenting as autosomal dominant, symptomatic, familial diabetes caused by a heterozygous HNF1A (MODY3) or HNF4A (MODY1) mutation, characterised by postprandial or progressive hyperglycemia and sensitivity to sulphonylureas.

Clinical Scenario

HNF1A-MODY is the most common form of monogenic diabetes that results in familial symptomatic diabetes. Heterozygous HNF1A mutations occur about ten times more frequently than heterozygous HNF4A mutations. Both HNF1A-MODY and HNF4A-MODY share notable sensitivity to sulphonylureas, a feature that distinguishes this group from common type 2 diabetes and directly informs treatment decisions.

Treatment Approach

Initial management involves dietary intervention, though marked postprandial hyperglycemia can occur — particularly with high-carbohydrate intake. The complete, structured regimen goes beyond this starting point.

Full treatment algorithm, sequencing, and evidence summary available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/pedi.13426

HNF1A-MODY is the most common form of monogenic diabetes that results in familial symptomatic diabetes, with heterozygous HNF1A mutations being about 10 times more frequent than heterozygous mutations in HNF4A.

Some forms of MODY are sensitive to SU, such as HNF1A-MODY and HNF4A-MODY.

Persons with both HNF1A and HNF4A-diabetes can initially be treated with diet although they will have marked postprandial hyperglycemia with high carbohydrate food.

View source ↗